Hemostasis Today
NewsFeed
Headlines Hematology Health Medicine VTE ASH Plasma Donation
Maxime Dely: The Vital Role of Plasma-Derived Clotting Factors in Rare Disease Care
Maxime Dely/LinkedIn
Sep 6, 2025, 12:46

Maxime Dely: The Vital Role of Plasma-Derived Clotting Factors in Rare Disease Care

Maxime Dely, Sales and Application Specialist in Therapeutic Apheresis and Cell Therapy, has shared a post on LinkedIn:

”Clotting factors: when plasma becomes a life-saving medicine

Plasma-derived medicinal products (PDMPs), such as factor VIII or IX concentrates, remain essential for patients living with rare and severe bleeding disorders

Conditions treated:

  • Hemophilia A and B (factor VIII or IX deficiency)
  • Rare congenital deficiencies (factor V, XI, XIII, protein S, plasminogen…)
  • Severe coagulation disorders linked to liver disease, trauma, or critical care situations

Across the world, millions of patients rely every year on plasma-derived medicines when recombinant alternatives are not yet available, effective, or well tolerated.

In many cases, these treatments are the only therapeutic option capable of preventing life-threatening bleeding and enabling a normal quality of life.

Behind every vial of medicine lies a plasma donation — transformed into treatment, hope, and survival for patients facing rare diseases.

How can we raise greater awareness of the vital role that plasma-derived coagulation factors play in rare disease care and innovation?”

Rare Disease

Stay updated on the emerging in transfusion medicine with Hemostasis Today.

clotting factors Factor IX Factor VIII Hematology Hemophilia A Hemophilia B Hemostasis Today Maxime Dely Medicine Plasma Donation Plasma-derived medicinal products Rare Disease thrombosis Transfusion Medicine
NewsFeed